Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis. Co.'s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand. Tegoprubart is engineered to improve safety and provide pharmacokinetic, pharmacodynamic and dosing advantages. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. We show 12 historical shares outstanding datapoints in our coverage of ELDN's shares outstanding history.
Understanding the changing numbers of ELDN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ELDN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ELDN by allowing them to research ELDN shares outstanding history
as well as any other stock in our coverage universe. |
Free ELDN Email Alerts:
Video: Shares Outstanding Importance
